Icatibant in viral infections

[1]  X. Solanich,et al.  Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial , 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Sjödin,et al.  Clinical and genomic characterisation of a fatal Puumala orthohantavirus case with low levels of neutralising antibodies , 2022, Infectious diseases.

[3]  A. Vaheri,et al.  Neutralizing Antibody Titers in Hospitalized Patients with Acute Puumala Orthohantavirus Infection Do Not Associate with Disease Severity , 2022, Viruses.

[4]  A. Vaheri,et al.  Severe Puumala virus infection in a patient with a lymphoproliferative disease treated with icatibant , 2015, Infectious diseases.

[5]  S. Meri,et al.  Pathophysiology of a severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. , 2014, Antiviral research.

[6]  A. Vaheri,et al.  Uncovering the mysteries of hantavirus infections , 2013, Nature Reviews Microbiology.

[7]  Shannon L. Taylor,et al.  Endothelial Cell Permeability during Hantavirus Infection Involves Factor XII-Dependent Increased Activation of the Kallikrein-Kinin System , 2013, PLoS pathogens.

[8]  J. Tenhunen,et al.  A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant , 2013, Scandinavian journal of infectious diseases.

[9]  B. Hellerstedt,et al.  Postsplenectomy cytomegalovirus mononucleosis is a distinct clinicopathologic syndrome. , 2010, The American journal of the medical sciences.

[10]  J. Mustonen,et al.  Pulmonary involvement in nephropathia epidemica: radiological findings and their clinical correlations. , 1996, Clinical nephrology.